Recombinant adeno-associated virus (AAV) vectors can safely deliver long-term (>2 years), high-titers (>200 ?g/ml) of antibody-like inhibitors to rhesus macaques. These titers are well above the IC90s of several broadly neutralizing HIV-1 antibodies. AAV vectors have an established safety record in humans, and risks associated with their use are modest, arguably lower than those associated with current antiviral regimens. If key hurdles can be surmounted, AAV-expressed transgenes could replace less-tolerated components of current combination therapies, or supplant these therapies entirely. An AAV-based approach would avoid toxicities, costs, and compliance concerns associated with current therapies. However some challenges remain. First, more experience with these vectors will be necessary to further increase confidence in their safety. Second, the relative in vivo efficacy of well-known HIV-1 neutralizing antibodies remains poorly described, especially in combination. Third, HIV-1 can escape antibodies passively administered to infected humans, although limitations of antibodies tested may have accelerated this escape. Finally, a minority of AAV-inoculated immune-sufficient macaques raise antibodies to and thereby clear expressed transgenes. The core purpose of these projects is to show that advances in AAV-based gene therapy now make possible stable, long-term suppression of HIV-1 replication. Our immediate goal is to stably suppress an ongoing SHIV-infection in rhesus macaques, using specific combinations of antiviral proteins delivered by AAV vectors. To do so, we will address directly the key challenges of safety, efficacy, viral escape, and immune clearance of expressed transgenes. We have assembled a team with outstanding, complementary experience in macaque models of infection (Ronald Desrosiers, Harvard Medical School), therapeutic use of AAV transgenes (Guangping Gao, U Mass Medical School), HIV-1 entry and its inhibition with neutralizing antibodies (Michael Farzan, Harvard Medical School), and phage-based development and improvement of human antibodies (MSM Protein Technologies, led by Tajib Mirzabekov). We first focus on the common goal of establishing of a system in which viral loads in SHIV-infected animals can be reproducibly suppressed. Aspects of this baseline system will then be optimized to increase transgene efficacy (Projects 1 and 3), prevent immune clearance (Projects 1 and 2), and limit viral escape (Projects 3 and 4). These studies will establish principles and protocols directly applicable to subsequent human clinical trials.

Public Health Relevance

Recombinant AAV-delivered transgenes have the potential to supplement or even replace conventional combination antiviral therapies, and have considerable advantages over these therapies. This program project will optimize the efficacy of AAV-delivered HIV-1 neutralizing antibodies and address the key hurdles of immune elimination of expressed transgenes and viral escape. In doing so, they will inform and motivate similar efforts in humans.

National Institute of Health (NIH)
National Institute of Allergy and Infectious Diseases (NIAID)
Research Program Projects (P01)
Project #
Application #
Study Section
Special Emphasis Panel (ZAI1-RB-A (J1))
Program Officer
Conley, Tony J
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
Scripps Florida
United States
Zip Code
Wang, Dan; Zhong, Li; Nahid, M Abu et al. (2014) The potential of adeno-associated viral vectors for gene delivery to muscle tissue. Expert Opin Drug Deliv 11:345-64
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part I. Gene delivery technologies. Discov Med 18:67-77
Quinlan, Brian D; Joshi, Vinita R; Gardner, Matthew R et al. (2014) A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. J Virol 88:3353-8
Wang, Dan; Gao, Guangping (2014) State-of-the-art human gene therapy: part II. Gene therapy strategies and clinical applications. Discov Med 18:151-61
Gao, Kai; Li, Mengxin; Zhong, Li et al. (2014) Empty Virions In AAV8 Vector Preparations Reduce Transduction Efficiency And May Cause Total Viral Particle Dose-Limiting Side-Effects. Mol Ther Methods Clin Dev 1:20139
Quinlan, Brian D; Gardner, Matthew R; Joshi, Vinita R et al. (2013) Direct expression and validation of phage-selected peptide variants in mammalian cells. J Biol Chem 288:18803-10
Stoica, Lorelei; Ahmed, Seemin S; Gao, Guangping et al. (2013) Gene transfer to the CNS using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit14D.5
Gruntman, Alisha M; Bish, Lawrence T; Mueller, Christian et al. (2013) Gene transfer in skeletal and cardiac muscle using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit 14D.3
Venkatesh, Aditya; Ma, Shan; Langellotto, Fernanda et al. (2013) Retinal gene delivery by rAAV and DNA electroporation. Curr Protoc Microbiol Chapter 14:Unit 14D.4
Ahmed, Seemin Seher; Li, Jia; Godwin, Jonathan et al. (2013) Gene transfer in the liver using recombinant adeno-associated virus. Curr Protoc Microbiol Chapter 14:Unit14D.6